After the breakthrough of using EGFR tyrosine kinase inhibitors in treatment for NSCLC, EGFR mutation testing in the non-invasive samples as peripheral blood has opened a new period of precision medicine. Here, EGFR is linked to non-small cell lung carcinoma.